Monotherapy with GI262570, a non-thiazolidinedione PPARγ agonist, improves glycemic control in type 2 diabetes mellitus patients (T2DM)

被引：0

作者：

Abou-Donia, M

Fiedorek, FT

Wilson, GG

Frith, L

Patel, J

机构：

[1] Glaxo Wellcome Co, Res Triangle Pk, NC USA

[2] PPA20005 Study Grp, Greenford, Middx, England

来源：

DIABETOLOGIA | 2000年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

726

引用

页码：A189 / A189

页数：1

共 50 条

[1] Monotherapy with GI262570, a tyrosine-based non-thiazolidinedione PPARγ agonist, improves metabolic control in Type 2 diabetes mellitus patients
Fiedorek, FT
Wilson, GG
Frith, L
Patel, J
Abou-Donia, M
DIABETES, 2000, 49 : A38 - A39
[2] GI262570, a non-thiazolidinedione PPARγ agonist, improves metabolic control in patients with type 2 diabetes mellitus when combined with glibenclamide treatment
Raz, I
Kler, L
Edwards, RC
McNeil, SJ
DIABETES, 2000, 49 : A129 - A129
[3] Monotherapy with GI262570, a non-thiazolidinedione PPARγ agonist, reduces triglyceride and increases HDL-C in patients with type 2 diabetes
Fiedorek, FT
Wilson, GG
Abou-Donia, M
Frith, L
Patel, J
DIABETOLOGIA, 2000, 43 : A189 - A189
[4] Monotherapy with GI262570, a tyrosine-based non-thiazolidinedione PPARγ agonist, significantly reduces triglyceride and increases HDL-C concentrations in patients with Type 2 diabetes mellitus
Wilson, GG
Abou-Donia, M
Frith, L
Patel, J
Fiedorek, FT
DIABETES, 2000, 49 : A39 - A39
[5] GI262570, a non-thiazolidinedione, tyrosine-based PPARγ agonist improves overall metabolic control in combination with glibenclamide
Raz, I
Kler, L
Edwards, R
McNeil, S
DIABETOLOGIA, 2000, 43 : A188 - A188
[6] Discovery and in vitro characterization of the novel, tyrosine-based, non-thiazolidinedione PPARγ agonist GI262570
Cobb, JE
Henke, BR
Blanchard, SG
DIABETOLOGIA, 2000, 43 : A189 - A189
[7] Weekly GLP-1 Agonist Albiglutide Monotherapy Improves Glycemic Parameters in Japanese Type 2 Diabetes Mellitus (T2DM) Patients
Nino, Antonio
Okuda, Inaha
Wilson, Timothy H.
Yue, Lin
Nakajima, Hiromu
Tsuboi, Maho
Carr, Molly C.
DIABETES, 2016, 65 : A266 - A266
[8] Empagliflozin Monotherapy for 12 Weeks Improves Glycemic Control in Japanese Patients With Type 2 Diabetes (T2DM)
Kadowaki, Takashi
Haneda, Masakazu
Inagaki, Nobuya
Taniguchi, Atsushi
Sakamoto, Masashi
Koiwai, Kazuki
Rattunde, Henning
Woerle, Hans J.
Broedl, Uli C.
DIABETES, 2013, 62 : A297 - A298
[9] Glycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients
Chen, Hsin-Hung
Horng, Ming-Hwarng
Yeh, Su-Yin
Lin, I-Ching
Yeh, Chih-Jung
Muo, Chih-Hsin
Sung, Fung-Chang
Kao, Chia-Hung
PLOS ONE, 2015, 10 (08):
[10] GlyCemic Control with Add-On Medication Use for Patients with Type 2 Diabetes Mellitus (T2DM) Who Failed Metformin Monotherapy
Fu, Alex Z.
Qiu, Ying
Radican, Larry
DIABETES, 2010, 59 : A612 - A613

← 1 2 3 4 5 →